Alterity Therapeutics (STU:PBN) 5-Year Share Buyback Ratio : -39.90% (As of Dec. 2024)

View and export this data going back to . Start your Free Trial

What is Alterity Therapeutics 5-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

5-Year Share Buyback Ratio measures the average annual proportion of a company's outstanding shares repurchased over the past five years. It is calculated as the annualized percentage change in shares outstanding from five years ago to the current year. A positive ratio may indicate share buybacks over the period, while a zero or negative ratio may reflect no repurchases or potential share issuance. Alterity Therapeutics's current 5-Year Share Buyback Ratio was -39.90%.

STU:PBN's 5-Year Share Buyback Ratio is ranked worse than
82.81% of 1152 companies
in the Biotechnology industry
Industry Median: -12.5 vs STU:PBN: -39.90

Competitive Comparison of Alterity Therapeutics's 5-Year Share Buyback Ratio

For the Biotechnology subindustry, Alterity Therapeutics's 5-Year Share Buyback Ratio, along with its competitors' market caps and 5-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alterity Therapeutics's 5-Year Share Buyback Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alterity Therapeutics's 5-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Alterity Therapeutics's 5-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Alterity Therapeutics 5-Year Share Buyback Ratio Calculation

This is the annualized percentage change in shares outstanding from five years ago to the current year. The annualized percentage change is calculated with least-square regression based on the latest six years of annual data on Shares Outstanding (EOP).

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Alterity Therapeutics (STU:PBN) 5-Year Share Buyback Ratio Explanation

A negative number means the company might be issuing new shares. A positive number indicates that the company is buying back shares.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Alterity Therapeutics 5-Year Share Buyback Ratio Related Terms

Thank you for viewing the detailed overview of Alterity Therapeutics's 5-Year Share Buyback Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

Alterity Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alterity Therapeutics Ltd (STU:PBN) » Definitions » 5-Year Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

PRNAF:USA ATHE:USA ATH:Australia

Address

350 Collins Street, Level 14, Melbourne, VIC, AUS, 3000

Website

https://www.alteritytherapeutics.com

Alterity Therapeutics Ltd is active in the healthcare domain. The company is engaged in research collaborations for the treatment of Parkinsonian movement disorders, Alzheimer's disease, Huntington disease, and other neurodegenerative disorders. The company's drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has a drug candidate for Parkinson's disease and other movement disorders (ATH434). The Group operated in one segment, being researching and developing Parkinsonian and other neurodegenerative disorders.

Alterity Therapeutics Headlines

No Headlines